Diabetes and Thyroid: New Guidelines for Closer Monitoring

New joint guidelines from leading German medical societies recommend significantly closer monitoring of thyroid function in people with diabetes, citing strong evidence that undiagnosed or poorly managed thyroid disorders can worsen blood sugar control and increase the risk of long-term complications.

The updated recommendations, issued by the German Diabetes Society (Deutsche Diabetes-Gesellschaft, DDG) in collaboration with the German Society of Endocrinology (Deutsche Gesellschaft für Endokrinologie, DGE), advise that all individuals diagnosed with either type 1 or type 2 diabetes undergo routine screening for thyroid dysfunction at the time of diagnosis and at regular intervals thereafter, particularly if they have additional risk factors such as autoimmune disease, family history of thyroid disorder, or symptoms suggestive of hypo- or hyperthyroidism.

For patients with type 1 diabetes, the guidelines emphasize annual thyroid-stimulating hormone (TSH) testing due to the well-established link between autoimmune thyroiditis (Hashimoto’s disease) and type 1 diabetes, both of which involve immune-mediated destruction of endocrine tissues. Studies cited in the guideline document show that up to 30% of people with type 1 diabetes also have autoimmune thyroid disease, compared to roughly 5% in the general population.

In those with type 2 diabetes, the association is less direct but still clinically significant. The guidelines note that hypothyroidism, even in subclinical forms, can contribute to insulin resistance, weight gain and dyslipidemia — factors that exacerbate metabolic dysfunction. Conversely, hyperthyroidism may accelerate glucose metabolism, leading to unpredictable blood sugar fluctuations and increased risk of hypoglycemia in patients using insulin or sulfonylureas.

“The interplay between thyroid function and glucose homeostasis is bidirectional and clinically meaningful,” said Dr. Petra Weber, an endocrinologist at Charité – Universitätsmedizin Berlin and one of the guideline’s lead authors. “Ignoring thyroid health in diabetic patients means missing a modifiable factor that can directly impact glycemic control, quality of life, and cardiovascular risk.”

The guidelines also address postpartum thyroiditis in women with gestational diabetes, recommending TSH screening at three and six months after delivery, given the heightened risk of transient or persistent thyroid dysfunction in this population. Untreated postpartum thyroiditis has been associated with an increased likelihood of developing permanent hypothyroidism and may interfere with glucose regulation during a critical postnatal period.

To support implementation, the societies recommend integrating thyroid screening into existing diabetes care pathways, such as annual comprehensive exams or visits for HbA1c measurement. They suggest using point-of-care TSH tests where available to reduce barriers to testing, particularly in primary care settings.

While the guidelines do not mandate universal thyroid ultrasound or antibody testing for all diabetic patients, they advise clinicians to measure thyroid peroxidase (TPO) antibodies when TSH levels are abnormal or when autoimmune thyroid disease is suspected, as positive antibodies help confirm autoimmune etiology and predict progression to overt thyroid dysfunction.

Importantly, the document stresses that treatment of thyroid dysfunction in diabetic patients should follow standard clinical protocols — levothyroxine for hypothyroidism, antithyroid medications or beta-blockers for hyperthyroidism — but with close monitoring of glucose levels during dose adjustments, as changes in thyroid status can rapidly alter insulin requirements.

The recommendations are based on a review of over 150 studies, including longitudinal cohort data, randomized controlled trials on subclinical thyroid treatment, and meta-analyses examining thyroid-diabetes comorbidity. The societies note that while treating subclinical hypothyroidism does not consistently improve HbA1c in all studies, symptom relief and lipid profile improvements justify treatment in symptomatic individuals, especially those with TSH levels above 10 mIU/L.

They call for further research into whether early intervention for thyroid dysfunction in prediabetic individuals can delay or prevent progression to type 2 diabetes, acknowledging that current evidence is observational but suggestive.

Both the DDG and DGE encourage healthcare systems to adopt these guidelines as part of standard diabetes care, arguing that proactive thyroid screening represents a low-cost, high-yield strategy to improve outcomes in a population already at elevated risk for cardiovascular, renal, and neuropathic complications.

As of April 2026, the guidelines are being disseminated through professional newsletters, continuing medical education modules, and integrated into clinical decision support tools in participating hospitals and clinics across Germany. The societies plan to evaluate adherence and outcomes through national diabetes registries over the next two years.